- Home
- EBS vs LAB Comparison
EBS vs LAB Comparison
Compare EBS & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- LAB
- Stock Information
- Founded
- EBS 1998
- LAB 1999
- Country
- EBS United States
- LAB United States
- Employees
- EBS N/A
- LAB N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- EBS Health Care
- LAB Industrials
- Exchange
- EBS Nasdaq
- LAB Nasdaq
- Market Cap
- EBS 529.9M
- LAB 449.9M
- IPO Year
- EBS 2006
- LAB 2011
- Fundamental
- Price
- EBS $10.93
- LAB $1.40
- Analyst Decision
- EBS Strong Buy
- LAB Hold
- Analyst Count
- EBS 1
- LAB 2
- Target Price
- EBS $15.00
- LAB $1.35
- AVG Volume (30 Days)
- EBS 1.5M
- LAB 2.1M
- Earning Date
- EBS 10-29-2025
- LAB 11-04-2025
- Dividend Yield
- EBS N/A
- LAB N/A
- EPS Growth
- EBS N/A
- LAB N/A
- EPS
- EBS 1.35
- LAB N/A
- Revenue
- EBS $788,900,000.00
- LAB $169,737,000.00
- Revenue This Year
- EBS N/A
- LAB N/A
- Revenue Next Year
- EBS $15.42
- LAB N/A
- P/E Ratio
- EBS $8.11
- LAB N/A
- Revenue Growth
- EBS N/A
- LAB 79.77
- 52 Week Low
- EBS $4.02
- LAB $0.92
- 52 Week High
- EBS $13.41
- LAB $2.25
- Technical
- Relative Strength Index (RSI)
- EBS 57.23
- LAB 63.18
- Support Level
- EBS $9.02
- LAB $1.16
- Resistance Level
- EBS $10.29
- LAB $1.46
- Average True Range (ATR)
- EBS 0.58
- LAB 0.08
- MACD
- EBS -0.03
- LAB 0.03
- Stochastic Oscillator
- EBS 93.69
- LAB 84.62
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.